Unknown

Dataset Information

0

Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.


ABSTRACT: The purpose of this study was to investigate the oncolytic potential of the recombinant, granulocyte macrophage colony-stimulating factor (GM-CSF)-expressing vaccinia virus (VV) JX-594 in experimental malignant glioma (MGs) in vitro and in immunocompetent rodent models. We have found that JX-594 killed all MG cell lines tested in vitro. Intratumoral (i.t.) administration of JX-594 significantly inhibited tumor growth and prolonged survival in rats-bearing RG2 intracranial (i.c.) tumors and mice-bearing GL261 brain tumors. Combination therapy with JX-594 and rapamycin significantly increased viral replication and further prolonged survival in both immunocompetent i.c. MG models with several animals considered "cured" (three out of seven rats >120 days, terminated experiment). JX-594 infected and killed brain tumor-initiating cells (BTICs) from patient samples grown ex vivo, and did so more efficiently than other oncolytic viruses MYXV, Reovirus type-3, and VSV(?M51). Additional safety/toxicity studies in nontumor-bearing rodents treated with a supratherapeutic dose of JX-594 demonstrated GM-CSF-dependent inflammation and necrosis. These results suggest that i.c. administered JX-594 triggers a predictable GM-CSF-mediated inflammation in murine models. Before proceeding to clinical trials, JX-594 should be evaluated in the brains of nonhuman primates and optimized for the viral doses, delivery routes as well as the combination agents (e.g., mTOR inhibitors).

SUBMITTER: Lun X 

PROVIDER: S-EPMC2990519 | biostudies-other | 2010 Nov

REPOSITORIES: biostudies-other

altmetric image

Publications

Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma.

Lun XueQing X   Chan Jennifer J   Zhou Hongyuan H   Sun Beichen B   Kelly John J P JJ   Stechishin Owen Owen OO   Bell John C JC   Parato Kelley K   Hu Kang K   Vaillant Dominique D   Wang Jiahu J   Liu Ta-Chiang TC   Breitbach Caroline C   Kirn David D   Senger Donna L DL   Forsyth Peter A PA  

Molecular therapy : the journal of the American Society of Gene Therapy 20100831 11


The purpose of this study was to investigate the oncolytic potential of the recombinant, granulocyte macrophage colony-stimulating factor (GM-CSF)-expressing vaccinia virus (VV) JX-594 in experimental malignant glioma (MGs) in vitro and in immunocompetent rodent models. We have found that JX-594 killed all MG cell lines tested in vitro. Intratumoral (i.t.) administration of JX-594 significantly inhibited tumor growth and prolonged survival in rats-bearing RG2 intracranial (i.c.) tumors and mice-  ...[more]

Similar Datasets

| S-EPMC10142208 | biostudies-literature
| S-EPMC8401401 | biostudies-literature
| 2108718 | ecrin-mdr-crc
2022-10-01 | GSE203101 | GEO
| S-EPMC2897629 | biostudies-literature
| 2109815 | ecrin-mdr-crc
| S-EPMC2798339 | biostudies-literature
| S-EPMC3553514 | biostudies-literature
| S-EPMC5545772 | biostudies-literature
| S-EPMC4068543 | biostudies-literature